Biomarker changes preceding symptom onset in genetic prion disease.

Sonia M VallabhMeredith A MortbergShona W AllenAshley C KupferschmidPia KivisäkkBruno L HammerschlagAnna BollingBianca A TrombettaKelli Devitte-McKeeAbaigeal M FordLauren SatherGriffin DuffyAshley RiveraJessica GerberAlison J McManusEric Vallabh Minikel Steven E Arnold

Published in: medRxiv : the preprint server for health sciences (2023)

mutations, CSF PrP levels are sufficiently stable to serve as a drug activity biomarker for PrP-lowering therapeutics and will not be confounded by disease-related molecular changes that precede symptom onset.

Keyphrases

platelet rich plasma
small molecule
genome wide
patient reported
emergency department
gene expression
drug induced
dna methylation